David N. Judelson
Keine laufenden Positionen mehr
Karriereverlauf von David N. Judelson
Ehemalige bekannte Positionen von David N. Judelson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Digital Compression Technology LP | Vorsitzender | 01.01.1993 | 17.09.2018 |
Biopure Corp.
Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 01.01.1984 | - |
Gründer | 17.11.2009 | - | |
Corporate Officer/Principal | 01.01.1984 | 17.11.2009 |
Ausbildung von David N. Judelson
New York University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Director/Board Member | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Biopure Corp.
Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
Digital Compression Technology LP |
- Börse
- Insiders
- David N. Judelson
- Erfahrung